Interventions: VK2735 Primary Outcome Measure: Percentage change in body weight from baseline for participants receiving VK2735 after 78 weeks of treatment Time Frame: 78 weeks Study Details Source VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) Sponsor: Viking Therapeutics Goal: This is a phase 3, multicenter, 78-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the weight loss efficacy as well as safety, tolerability, pharmacodynamic effects, and pharmacokinetics of VK2735 in adults with Type 2 Diabetes who are obese or overweight
Dosage Shake lightly before each use
Hydrolyzed Bovine Collagen for Skin Renewal Collagen is the most important structural protein in the human body
Graves orbitopathy (GO) is the most prominent and common extrathyroidal manifestation of GD, characterized by the production and accumulation of glycosaminoglycans (especially hyaluronic acid) in the retrobulbar and periorbital tissues causing protrusion of the eyeball and restriction of ocular muscle movement (10)
An Ozempic lawyer represents people who took Ozempic, experienced serious complications, and choose to file a lawsuit
von HS, Morley JE, Anker SD
